Toll Free: 1-888-928-9744
Published: May, 2015 | Pages:
45 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Dr. Falk Pharma GmbH - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Dr. Falk Pharma GmbH - Product Pipeline Review - 2015', provides an overview of the Dr. Falk Pharma GmbH's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Dr. Falk Pharma GmbH's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Dr. Falk Pharma GmbH including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Dr. Falk Pharma GmbH's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Dr. Falk Pharma GmbH's pipeline products Reasons to buy - Evaluate Dr. Falk Pharma GmbH's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Dr. Falk Pharma GmbH in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Dr. Falk Pharma GmbH's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Dr. Falk Pharma GmbH and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Dr. Falk Pharma GmbH - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Explore the dormant and discontinued projects of Dr. Falk Pharma GmbH and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Dr. Falk Pharma GmbH Snapshot 5 Dr. Falk Pharma GmbH Overview 5 Key Information 5 Key Facts 5 Dr. Falk Pharma GmbH - Research and Development Overview 6 Key Therapeutic Areas 6 Dr. Falk Pharma GmbH - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Partnered Products 10 Partnered Products/Combination Treatment Modalities 11 Dr. Falk Pharma GmbH - Pipeline Products Glance 12 Dr. Falk Pharma GmbH - Late Stage Pipeline Products 12 Phase III Products/Combination Treatment Modalities 12 Dr. Falk Pharma GmbH - Clinical Stage Pipeline Products 13 Phase II Products/Combination Treatment Modalities 13 Phase I Products/Combination Treatment Modalities 14 Dr. Falk Pharma GmbH - Early Stage Pipeline Products 15 Preclinical Products/Combination Treatment Modalities 15 Dr. Falk Pharma GmbH - Unknown Stage Pipeline Products 16 Unknown Products/Combination Treatment Modalities 16 Dr. Falk Pharma GmbH - Drug Profiles 17 budesonide 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 LT-02 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 mesalamine 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 rifamycin 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 norursodeoxycholic acid 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 udenafil 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 RhuDex 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 ZED-1227 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 ZED-101 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Dr. Falk Pharma GmbH - Pipeline Analysis 32 Dr. Falk Pharma GmbH - Pipeline Products by Target 32 Dr. Falk Pharma GmbH - Pipeline Products by Route of Administration 33 Dr. Falk Pharma GmbH - Pipeline Products by Molecule Type 34 Dr. Falk Pharma GmbH - Pipeline Products by Mechanism of Action 35 Dr. Falk Pharma GmbH - Recent Pipeline Updates 36 Dr. Falk Pharma GmbH - Dormant Projects 41 Dr. Falk Pharma GmbH - Discontinued Pipeline Products 42 Discontinued Pipeline Product Profiles 42 CNDO-201 42 mesalamine 42 Dr. Falk Pharma GmbH - Locations And Subsidiaries 43 Head Office 43 Other Locations & Subsidiaries 43 Appendix 44 Methodology 44 Coverage 44 Secondary Research 44 Primary Research 44 Expert Panel Validation 44 Contact Us 44 Disclaimer 45
List of Tables Dr. Falk Pharma GmbH, Key Information 5 Dr. Falk Pharma GmbH, Key Facts 5 Dr. Falk Pharma GmbH - Pipeline by Indication, 2015 7 Dr. Falk Pharma GmbH - Pipeline by Stage of Development, 2015 8 Dr. Falk Pharma GmbH - Monotherapy Products in Pipeline, 2015 9 Dr. Falk Pharma GmbH - Partnered Products in Pipeline, 2015 10 Dr. Falk Pharma GmbH - Partnered Products/ Combination Treatment Modalities, 2015 11 Dr. Falk Pharma GmbH - Phase III, 2015 12 Dr. Falk Pharma GmbH - Phase II, 2015 13 Dr. Falk Pharma GmbH - Phase I, 2015 14 Dr. Falk Pharma GmbH - Preclinical, 2015 15 Dr. Falk Pharma GmbH - Unknown, 2015 16 Dr. Falk Pharma GmbH - Pipeline by Target, 2015 32 Dr. Falk Pharma GmbH - Pipeline by Route of Administration, 2015 33 Dr. Falk Pharma GmbH - Pipeline by Molecule Type, 2015 34 Dr. Falk Pharma GmbH - Pipeline Products by Mechanism of Action, 2015 35 Dr. Falk Pharma GmbH - Recent Pipeline Updates, 2015 36 Dr. Falk Pharma GmbH - Dormant Developmental Projects,2015 41 Dr. Falk Pharma GmbH - Discontinued Pipeline Products, 2015 42 Dr. Falk Pharma GmbH, Subsidiaries 43
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.